RxDoctor Payments DataLook up a doctor →

Marisol Ocampo

Nurse Practitioner · Miami Beach, FLNPI 1457859720

Payments from drug & device makers

$32,342in general payments, 2019–2025

Across 1,296 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AstraZeneca$2K
  • Pfizer$2K
  • Bristol Myers Squibb$2K
  • Sanofi$2K
  • Daiichi Sankyo Inc.$1K
  • plus $20K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)173$3,489
AstraZeneca(2 entities)85$2,000
Pfizer70$1,866
Bristol Myers Squibb75$1,595
Sanofi28$1,548
Daiichi Sankyo Inc.36$1,265
Novartis65$1,162
Merck45$979
Incyte Corporation35$910
Eisai Inc.39$839
Beigene USA, Inc.30$767
E.r. Squibb & Sons, L.L.C.20$766
Astellas Pharma US Inc36$696
Karyopharm Therapeutics Inc.1$660
Genentech USA, Inc.35$659
Amgen38$637
Regeneron Healthcare Solutions, Inc.14$598
Array Biopharma Inc33$554
Janssen Scientific Affairs, LLC1$540
Bayer28$538
GSK20$528
AbbVie22$510
Seagen Inc.21$486
Epizyme, Inc.10$461
Springworks Therapeutics, Inc.13$427
Tempus AI, Inc9$391
Adaptive Biotechnologies Corporation14$389
Sirtex Medical Inc3$356
Exelixis Inc.18$352
EMD Serono, Inc.21$336
Sumitomo Pharma America, Inc.14$321
ADC Therapeutics America, Inc.11$296
Pharmacyclics LLC, An Abbvie Company12$288
Takeda Pharmaceuticals U.S.A., Inc.14$278
Beone Medicines USA, Inc.8$278
Deciphera Pharmaceuticals Inc.13$271
Gilead(2 entities)8$238
Myovant Sciences Inc.10$232
Jazz Pharmaceuticals Inc.8$232
Sobi, Inc6$230
Mirati Therapeutics, Inc.11$219
Taiho Oncology, Inc.9$214
Rigel Pharmaceuticals, Inc.2$208
Lilly USA, LLC9$170
Ipsen Biopharmaceuticals, Inc9$168
Myriad Genetic Laboratories, Inc.9$164
Morphosys, US Inc.8$157
AVEO Pharmaceuticals, Inc.6$152
Genmab U.S., Inc.6$132
Servier Pharmaceuticals LLC4$109
Immunogen, Inc.1$106
Boehringer Ingelheim4$102
Blueprint Medicines Corporation5$96
Stemline Therapeutics Inc.6$94
Tersera Therapeutics LLC3$90
Foundation Medicine, Inc.5$87
Sanofi US Services Inc.1$83
Dendreon Pharmaceuticals LLC3$73
Acceleron Pharma, Inc.4$72
Kyowa Kirin, Inc.4$72

How this compares

$32,342 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida →

Medicare billing

Part B allowed, 2024
$13,870
Medicare patients
131
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Miami Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →